RxDoctor Payments Data

Mohini Gurme, MD

Clinical Neurophysiology · West Nyack, NYNPI 1316173156

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 637 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 60 manufacturers reported payments, led by AbbVie at 28.1% of the total. Among clinical neurophysiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,972in general payments, 2019–2025

Across 637 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Lilly USA, LLC$677
  • Eisai Inc.$552
  • Novartis$488
  • EMD Serono, Inc.$426
  • SK Life Science, Inc.$425
  • plus $7K from 54 others

What the payments were for

  • Speaking & faculty fees$190%
  • Food & beverage$12,927100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)163$3,639
Lilly USA, LLC41$677
Eisai Inc.24$552
Novartis32$488
EMD Serono, Inc.20$426
SK Life Science, Inc.17$425
Kyowa Kirin, Inc.18$371
Amgen17$355
UCB, Inc.17$319
Pfizer18$286
Lundbeck LLC12$286
Sanofi14$284
Adamas Pharmaceuticals, Inc.17$281
Supernus Pharmaceuticals, Inc.17$274
Grifols USA, LLC12$268
Biohaven Pharmaceuticals, Inc.14$233
AstraZeneca(2 entities)11$219
Acadia Pharmaceuticals Inc11$213
Amneal Pharmaceuticals LLC12$210
Biogen10$204
Johnson & Johnson(2 entities)6$202
Genentech USA, Inc.8$189
Argenx US, Inc.6$187
Upsher-smith Laboratories LLC10$171
Sumitomo Pharma America, Inc.7$141
Avanir Pharmaceuticals, Inc.6$141
Tanabe Pharma America, Inc.7$132
Currax Pharmaceuticals LLC9$116
Aucta Pharmaceuticals, Inc.7$109
Assertio Therapeutics, Inc.6$106
Neurelis, Inc.3$106
Arbor Pharmaceuticals, Inc.7$99
CSL Behring4$97
Almatica Pharma LLC3$89
Bristol Myers Squibb5$83
Vertical Pharmaceuticals, LLC4$77
Catalyst Pharmaceuticals, Inc.3$71
Genentech, Inc.1$64
Medtronic3$61
Biohaven Pharmaceutical Holding Company Ltd.3$60
Neurocrine Biosciences, Inc.3$56
Otsuka America Pharmaceutical, Inc.2$52
Sunovion Pharmaceuticals Inc.2$50
Portola Pharmaceuticals, LLC2$49
Impel Pharmaceuticals Inc.2$48
Abbott2$47
Azurity Pharmaceuticals, Inc.2$44
Axsome Therapeutics, Inc.2$43
Aprecia Pharmaceuticals, LLC3$42
Boston Scientific1$29
Teva Pharmaceuticals USA, Inc.2$26
TG Therapeutics, Inc.1$25
Xeris Pharmaceuticals, Inc.1$24
Cala Health, Inc.1$21
Mallinckrodt Hospital Products Inc.1$21
Acorda Therapeutics, Inc1$19
Mallinckrodt Enterprises LLC1$18
Life Molecular Imaging Ltd1$17
Alnylam Pharmaceuticals Inc.1$17
Bausch Health US, LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,972 in reported general payments places this provider in the 90th percentile of 35 clinical neurophysiology providers in New York.

See all clinical neurophysiology providers in New York

Medicare billing

Part B allowed, 2024
$87,424
Medicare patients
254
Services billed
3,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FycompaPerampanel27$15,542
Aimovig AutoinjectorErenumab-Aooe11$11,108
Levetiracetam102$4,886
Lacosamide51$3,511
Memantine Hcl44$2,121
Gabapentin108$1,352
Carbidopa-LevodopaCarbidopa/Levodopa44$1,312
Pregabalin25$1,183
Topiramate43$1,113
Donepezil Hcl86$958
Primidone14$869
Quetiapine Fumarate19$780
Lamotrigine42$630
Divalproex Sodium23$583
Amitriptyline Hcl18$509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$552$15,54227 claims
Upsher-smith Laboratories LLCTopiramate$171$1,11343 claims
Almatica Pharma LLCSertraline Hcl$89$37024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 35 clinical neurophysiology providers in New York.

Other clinical neurophysiology in West Nyack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →